Redmile Group, LLC

Registered adviser

CIK

1425738

Location

Larkspur, CA

Portfolio Value

Mid $1,489,507,486

Diversification

Diversified

Filing Date

Global Rank

#1,965 / 8,827 ▼ 212

Top Industry

Biotechnology 97.6%

Period ended 4 months ago

Filed Aug 14, 2026 · 3mo

26 quarters · since Mar 2020

Regulatory profile

From Form ADV, the SEC filer profile, 13D/13G type codes and N-CEN, never from the name.

Holder type

Registered adviser

Form ADV roster, Nov 1, 2026

Form ADV adviser

CRD 143606

Roster of Nov 1, 2026

Regulatory AUM

$4,701,099,967

Main clients

Pooled investment vehicles (100% of AUM)

Private funds

20 funds · Mixed

Focus by fund count, roster of Nov 1, 2026

$4,648,184,295 gross assets

LEI

5493007T2I6TUUZ37I60

Private funds on Schedule D 7.B.(1)

As filed Jul 3, 2024; SEC's bulk Form ADV archive ends with 2024 filings.

$7,202,682,127 gross assets in 18 funds Hedge funds $4,525,974,872 (8) Venture capital funds $1,478,308,062 (7) Private equity funds $1,198,399,193 (3)

Form ADV history

Monthly rosters from Dec 2019; each row is a run with the same figures, newest first.

Rosters	Regulatory AUM	Main clients
Sep 2026 to Nov 2026	$4,701,099,967	Pooled investment vehicles (100%)
Apr 2026 to Aug 2026	$4,701,099,967	Pooled investment vehicles (100%)
Mar 2026	$4,835,026,495	Pooled investment vehicles (100%)
Apr 2025 to Feb 2026	$4,835,026,495	Pooled investment vehicles (100%)
Apr 2024 to Mar 2025	$6,473,965,022	Pooled investment vehicles (100%)
May 2023 to Mar 2024	$7,236,737,898	Pooled investment vehicles (100%)

5 earlier changes not shown.

Schedule 13D/13G stakes

Stakes of 5% or more disclosed on Schedule 13D or 13G, each on the filer's latest filing for the security. These are event-dated stakes, not the quarter-end 13F portfolio below.

Company	Schedule	Event date	Filed	Shares	% of class	Change	Status
ETRA Electra Therapeutics, Inc.	13G	Sep 21, 2026	40d	5,462,881	8.7%	—	Current
ATRA Atara Biotherapeutics, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Jul 22, 2026	4mo	950,994	9.9%	0 since May 12, 2026	Current
STTK Shattuck Labs, Inc.	13D/A not restated by this amendment, the earlier 13D's purpose stands	Jul 15, 2026	4mo	10,019,421	9.9%	+200,337 since Jun 9, 2026	Current
ANNX Annexon, Inc.	13G/A	Jul 1, 2026	4mo	17,918,459	9.9%	+2,490,593 since Dec 31, 2025	Current
NGNE Neurogene Inc.	13G/A	Jun 30, 2026	3mo	1,572,202	9.9%	+15,023 since Dec 31, 2025	Current
NRIX Nurix Therapeutics, Inc.	13G/A	Jun 30, 2026	3mo	8,782,256	8.1%	-1,914,058 since Apr 20, 2026	Current
ADCT ADC Therapeutics SA	13G/A	Apr 20, 2026	7mo	12,717,487	9.9%	+24,646 since Apr 6, 2026	Current
FATE Fate Therapeutics Inc	13D/A not restated by this amendment, the earlier 13D's purpose stands	Apr 20, 2026	7mo	18,229,078	14.9%	+287,499 since Jul 2, 2025	Current
AGMB AgomAb Therapeutics NV	13G	Mar 31, 2026	6mo	2,735,926	5.6%	—	Current
ALXO Alx Oncology Holdings Inc	13G/A	Mar 31, 2026	6mo	9,214,188	6.8%	+4,572,733 since Jun 30, 2025	Current
STOK Stoke Therapeutics, Inc.	13G/A	Mar 31, 2026	6mo	4,164,120	6.7%	-211,811 since Jun 30, 2025	Current
RGNX REGENXBIO Inc.	13G/A	Jun 30, 2025	1y	5,062,477	9.9%	+120,165 since Sep 30, 2024	Current

A 13D or 13G stays in force until its filer amends it and no amendment is due without a material change, so a stake with no filing in 24 months reads unconfirmed, never sold. An amendment reporting under 5% ends the filer's duty to amend, not necessarily the holding. Shares are restated onto today's split basis. Show 23 exited, below-5% or retired stakes

Portfolio style

Measured from the filed 13F common-share book for Jun 30, 2026, never from the firm's own description.

Style

Concentrated

The top 10 positions are 73.5% of the book (60%+)

Turnover

Medium turnover

30.0% over the last four quarters (30% to under 100%)

Horizon

Long horizon

Value-weighted holding period 20.5 quarters (12+), a floor since 49.2% of the book was already held when coverage starts

Closest benchmark: the Russell 2000 as of 2026-06-30, active share 98.0%; sector active share 90.9% against the combined 13F book's sector weights.

Over time 26 measured quarters

How the bands are measured

Style bands measure the filed 13F common-share book each closed quarter, tested in this order. Unknown: under $10,000,000 of valued equity or 5 stocks. Index-like (100+ stocks): active share of 20% or less against the closest benchmark, which is the S&P 500, S&P MidCap 400, S&P SmallCap 600, Russell 1000, Russell 2000, Nasdaq-100 or Dow Jones Industrial Average (weighted by an index-tracking fund's reported holdings or the index's constituents nearest the quarter end, over the names resolved to companies, and only when those are 90%+ of its weight) or every 13F filer's combined book, or index series holding 80%+ of the registered fund assets it advises (N-CEN) and equal to 50%+ of its book. Systematic-like: 500+ stocks, 100%+ annual turnover and a top 10 weight of 25% or less. Concentrated: a top 10 weight of 60%+ or 12 or fewer effective positions. Diversified active: none of these. Turnover is the smaller of buys and sells over average equity value, summed over four quarters: low under 30%, high 100%+. Horizon is the value-weighted number of quarters each position has been held: short under 4, long 12+.

Clone Performance

Build a hypothetical price-return history from this filer's public 13F holdings.

View clone backtest

Portfolio Concentration

39 tracked positions · as of Jun 30, 2026 · Δ vs Mar 31, 2026

Top Position

15.9%

−13.6 pts

Top 5

54.0%

−12.0 pts

Top 10

73.5%

−8.4 pts

HHI

787

Diversified−503

Portfolio Trend

26 quarters · across all stocks

Sector Breakdown

As of Jun 30, 2026

Sector	% Portfolio	Value	Positions
Healthcare	100.0%	$1,489,507,486	39

Last Quarter's Activity

Export CSV

Jun 30, 2026 vs Mar 31, 2026

Added To

Positions the filer increased

5 positions

Ticker	Company	Δ Shares	Shares	Value
AGMB	AgomAb Therapeutics NV	+2,577,676	2,733,926	$35,486,359
STTK	Shattuck Labs, Inc.	+1,352,309	6,892,033	$47,830,709
CLDX	Celldex Therapeutics, Inc.	+172,413	433,921	$16,146,200
IDYA	IDEAYA Biosciences, Inc.	+119,085	640,202	$23,860,328
BMRN	Biomarin Pharmaceutical Inc	+91,310	265,169	$15,172,970
No positions match the current search.

Trimmed

Positions the filer reduced

23 positions

Ticker	Company	Δ Shares	Shares	Value
SRRK	Scholar Rock Holding Corp	−4,755,529	4,311,092	$237,110,060
ADCT	ADC Therapeutics SA	−3,943,792	11,526,710	$12,333,579
NRIX	Nurix Therapeutics, Inc.	−3,659,021	4,073,787	$98,830,072
ANNX	Annexon, Inc.	−2,679,891	11,869,877	$67,776,997
ABSI	Absci Corp	−1,513,641	6,739,675	$78,112,833
IMNM	Immunome Inc.	−647,295	4,911,590	$104,076,592
ALXO	Alx Oncology Holdings Inc	−571,684	7,392,504	$15,302,483
STOK	Stoke Therapeutics, Inc.	−218,200	3,945,920	$129,110,502
PRME	Prime Medicine, Inc.	−201,200	1,389,632	$5,127,742
COGT	Cogent Biosciences, Inc.	−184,715	503,321	$19,478,522
NUVB	Nuvation Bio Inc.	−122,247	3,031,009	$17,216,131
ARDX	Ardelyx, Inc.	−91,600	641,750	$3,272,925
EPRX	Eupraxia Pharmaceuticals Inc.	−88,600	611,400	$4,041,354
DBVT	DBV Technologies S.A.	−80,900	410,440	$6,731,216
BEAM	Beam Therapeutics Inc.	−73,400	1,164,259	$39,957,368
SLDB	Solid Biosciences Inc.	−63,200	1,948,695	$19,467,463
ORIC	Oric Pharmaceuticals, Inc.	−53,700	362,010	$3,920,568
IVVD	Invivyd, Inc.	−50,900	2,597,759	$2,265,245
NGNE	Neurogene Inc.	−47,400	1,412,199	$44,413,658
KRYS	Krystal Biotech, Inc.	−41,500	632,005	$234,897,298
XENE	Xenon Pharmaceuticals Inc.	−33,300	229,374	$13,845,014
LIVN	LivaNova PLC	−15,200	93,154	$7,660,053
ESTA	Establishment Labs Holdings Inc.	−14,500	88,964	$7,634,000
No positions match the current search.

New Positions

Positions the filer opened this quarter

4 positions

Ticker	Company	Shares	Value
CLYM	Climb Bio, Inc.	1,226,330	$15,991,343
AURA	Aura Biosciences, Inc.	1,666,667	$11,833,335
ODTX	Odyssey Therapeutics, Inc.	425,000	$7,951,750
INSM	INSMED Inc	51,234	$5,462,569
No positions match the current search.

Sold Out

Positions the filer fully exited

No qualifying positions this quarter.

Portfolio Positions

Compact Export CSV View 13F filing

39 tracked positions · $1,489,507,486 total · filing declares 39 positions · $1,489,508,540 · as of Jun 30, 2026

All sectors Healthcare

Ticker	Company	Type	Shares	Δ Shares	Value (USD)	% Δ Value	Held (qtrs)	Est. cost/share	% of Portfolio
SRRK	Scholar Rock Holding Corp Healthcare	Reduced	4,311,092	-4,755,529	$237,110,060	−46.8%	26+	before history	15.92%
KRYS	Krystal Biotech, Inc. Healthcare	Reduced	632,005	-41,500	$234,897,298	+35.0%	26+	before history	15.77%
STOK	Stoke Therapeutics, Inc. Healthcare	Reduced	3,945,920	-218,200	$129,110,502	−4.8%	26+	before history	8.67%
IMNM	Immunome Inc. Healthcare	Reduced	4,911,590	-647,295	$104,076,592	−14.4%	11	$11.49	6.99%
NRIX	Nurix Therapeutics, Inc. Healthcare	Reduced	4,073,787	-3,659,021	$98,830,072	−17.5%	24	$17.18	6.64%
ABSI	Absci Corp Healthcare	Reduced	6,739,675	-1,513,641	$78,112,833	+215.5%	20	$19.01	5.24%
ANNX	Annexon, Inc. Healthcare	Reduced	11,869,877	-2,679,891	$67,776,997	−15.9%	24	$8.51	4.55%
RGNX	REGENXBIO Inc. Healthcare	Held	4,368,804	0	$52,338,271	+43.0%	26+	before history	3.51%
STTK	Shattuck Labs, Inc. Healthcare	Added	6,892,033	+1,352,309	$47,830,709	+34.3%	23	$27.06	3.21%
NGNE	Neurogene Inc. Healthcare	Reduced	1,412,199	-47,400	$44,413,658	+50.9%	11	unpriced	2.98%
BEAM	Beam Therapeutics Inc. Healthcare	Reduced	1,164,259	-73,400	$39,957,368	+35.5%	26+	before history	2.68%
AGMB	AgomAb Therapeutics NV Healthcare	Added	2,733,926	+2,577,676	$35,486,359	+2065.0%	2	$11.42	2.38%
FATE	Fate Therapeutics Inc Healthcare	Held	12,872,946	0	$34,756,954	+125.0%	26+	before history	2.33%
IDYA	IDEAYA Biosciences, Inc. Healthcare	Added	640,202	+119,085	$23,860,328	+37.4%	11	$28.07	1.60%
SLN	Silence Therapeutics plc Healthcare	Held	2,164,777	0	$23,769,251	+108.3%	10	$19.90	1.60%
COGT	Cogent Biosciences, Inc. Healthcare	Reduced	503,321	-184,715	$19,478,522	−26.4%	13	$9.95	1.31%
SLDB	Solid Biosciences Inc. Healthcare	Reduced	1,948,695	-63,200	$19,467,463	+34.4%	7	$4.78	1.31%
NUVB	Nuvation Bio Inc. Healthcare	Reduced	3,031,009	-122,247	$17,216,131	+27.3%	22	$10.97	1.16%
CLDX	Celldex Therapeutics, Inc. Healthcare	Added	433,921	+172,413	$16,146,200	+94.6%	25	$19.82	1.08%
CLYM	Climb Bio, Inc. Healthcare	NEW	1,226,330	NEW	$15,991,343	NEW	1	$10.33	1.07%
ALXO	Alx Oncology Holdings Inc Healthcare	Reduced	7,392,504	-571,684	$15,302,483	−4.2%	24	$7.46	1.03%
BMRN	Biomarin Pharmaceutical Inc Healthcare	Added	265,169	+91,310	$15,172,970	+54.5%	2	$57.09	1.02%
XENE	Xenon Pharmaceuticals Inc. Healthcare	Reduced	229,374	-33,300	$13,845,014	−9.4%	3	$44.00	0.93%
ZYME	Zymeworks Inc. Healthcare	Held	491,654	0	$12,851,835	+4.4%	15	$7.05	0.86%
ADCT	ADC Therapeutics SA Healthcare	Reduced	11,526,710	-3,943,792	$12,333,579	−78.7%	25	$19.36	0.83%
AURA	Aura Biosciences, Inc. Healthcare	NEW	1,666,667	NEW	$11,833,335	NEW	1	$7.15	0.79%
ODTX	Odyssey Therapeutics, Inc. Healthcare	NEW	425,000	NEW	$7,951,750	NEW	1	$17.54	0.53%
LIVN	LivaNova PLC Healthcare	Reduced	93,154	-15,200	$7,660,053	+11.2%	22	$70.40	0.51%
ESTA	Establishment Labs Holdings Inc. Healthcare	Reduced	88,964	-14,500	$7,634,000	+29.9%	10	$44.21	0.51%
CBLL	Ceribell, Inc. Healthcare	Held	386,786	0	$7,522,987	+6.1%	7	$27.25	0.51%
DBVT	DBV Technologies S.A. Healthcare	Reduced	410,440	-80,900	$6,731,216	−34.4%	3	$15.63	0.45%
INSM	INSMED Inc Healthcare	NEW	51,234	NEW	$5,462,569	NEW	1	$121.09	0.37%
PRME	Prime Medicine, Inc. Healthcare	Reduced	1,389,632	-201,200	$5,127,742	−7.4%	2	$3.81	0.34%
ATRA	Atara Biotherapeutics, Inc. Healthcare	Held	441,701	0	$5,070,727	+142.7%	26+	before history	0.34%
EPRX	Eupraxia Pharmaceuticals Inc. Healthcare	Reduced	611,400	-88,600	$4,041,354	−20.3%	2	$8.05	0.27%
ORIC	Oric Pharmaceuticals, Inc. Healthcare	Reduced	362,010	-53,700	$3,920,568	−25.6%	3	$11.51	0.26%
ARDX	Ardelyx, Inc. Healthcare	Reduced	641,750	-91,600	$3,272,925	−25.5%	2	$6.62	0.22%
IVVD	Invivyd, Inc. Healthcare	Reduced	2,597,759	-50,900	$2,265,245	−34.2%	20	$16.17	0.15%
PLRX	Pliant Therapeutics, Inc. Healthcare	Held	772,126	0	$880,223	−9.5%	25	$22.45	0.06%

Covers the securities this platform tracks: U.S.-listed common stock and the put/call positions reported on it. A 13F can also report security types outside that coverage — preferred shares, bonds, warrants, untracked share classes — so the filing's own declared total can exceed the figures above. The source filing is linked at the top of this table.